Table 2.

Characteristics of patients with GT3-HCV infection who experienced viral relapse after stopping sofosbuvir containing treatment regime

No.	Age	Gender	Route of Infection	HCV RNA	ALT	AST	TBil	PLT	Cirrhosis	FIB-4	APRI	Treatment
												Strategy	Actual Duration
1	48	M	Unknown	4.34	73	87	18.4	132	no	3.70	1.65	SOF + DCV	12
2	50	M	Travenous drug abuse	6.30	46	70	16.2	117	no	4.41	1.50	SOF + DCV	12
3	25	F	Travenous drug abuse	6.54	52	84	17.7	152	no	1.92	1.38	SOF + DCV	12
4	73	M	Blood products	4.16	155	217	29.5	32	yes	39.76	16.95	SOF + DCV	24
5	35	M	Travenous drug abuse	6.85	24.6	47.7	28.2	34	yes	9.90	3.51	SOF + DCV + RB	12
6	37	M	Unknown	7.35	72.1	115.8	29	182	yes	2.77	1.59	SOF + DCV + RB	12
7	36	M	Travenous drug abuse	6.98	331	221	29.1	82	yes	5.33	6.74	SOF + DCV	24
8	41	M	Travenous drug abuse	6.53	124	144	17.3	82	yes	6.47	4.399	SOF + DCV	12
9	43	F	Travenous drug abuse	6.00	100	100	13.2	34	yes	12.65	7.35	SOF + DCV	12
10	48	F	Blood products	7.06	81	122.8	12.6	59	no	11.10	5.20	SOF + DCV	12